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Background: Overt hypothyroidism has been found to
be associated with cardiovascular disease. Whether sub-
clinical hypothyroidism and thyroid autoimmunity are also
risk factors for cardiovascular disease is controversial.
Objective: To investigate whether subclinical hypo-
thyroidism and thyroid autoimmunity are associated with
aortic atherosclerosis and myocardial infarction in post-
menopausal women.
Design: Population-based cross-sectional study.
Setting: A district of Rotterdam, the Netherlands.
Participants: Random sample of 1149 women (mean age
6 SD, 69.0 6 7.5 years) participating in the Rotterdam
Study.
Measurements: Data on thyroid status, aortic athero-
sclerosis, and history of myocardial infarction were ob-
tained at baseline. Subclinical hypothyroidism was defined
as an elevated thyroid-stimulating hormone level (.4.0
mU/L) and a normal serum free thyroxine level (11 to 25
pmol/L [0.9 to 1.9 ng/dL]). In tests for antibodies to thyroid
peroxidase, a serum level greater than 10 IU/mL was con-
sidered a positive result.
Results: Subclinical hypothyroidism was present in
10.8% of participants and was associated with a greater
age-adjusted prevalence of aortic atherosclerosis (odds
ratio, 1.7 [95% CI, 1.1 to 2.6]) and myocardial infarction
(odds ratio, 2.3 [CI, 1.3 to 4.0]). Additional adjustment for
body mass index, total and high-density lipoprotein cho-
lesterol level, blood pressure, and smoking status, as well
as exclusion of women who took b-blockers, did not affect
these estimates. Associations were slightly stronger in
women who had subclinical hypothyroidism and antibod-
ies to thyroid peroxidase (odds ratio for aortic atheroscle-
rosis, 1.9 [CI, 1.1 to 3.6]; odds ratio for myocardial infarc-
tion, 3.1 [CI, 1.5 to 6.3]). No association was found between
thyroid autoimmunity itself and cardiovascular disease.
The population attributable risk percentage for subclinical
hypothyroidism associated with myocardial infarction was
within the range of that for known major risk factors for
cardiovascular disease.
Conclusion: Subclinical hypothyroidism is a strong indi-
cator of risk for atherosclerosis and myocardial infarction
in elderly women.
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Overt hypothyroidism, with its accompanyinghypercholesterolemia and hypertension, has
been found to be associated with cardiovascular dis-
ease (1–3). Subclinical hypothyroidism, defined as
an asymptomatic state characterized by normal se-
rum concentrations of free thyroxine and elevated
serum concentrations of thyroid-stimulating hor-
mone (TSH) (4), is highly prevalent in elderly
women (5, 6). Whether subclinical hypothyroidism
is related to risk for cardiovascular disease is contro-
versial. Case–control and cross-sectional studies on
the association between subclinical hypothyroidism
and cardiovascular disease have been done (7–11).
Results from these studies are not consistent, but
many of the studies were small. The same contro-
versy surrounds thyroid autoimmunity. In the late
1960s and early 1970s, autopsy studies (12, 13) and
studies in hospital inpatients (12, 14) suggested that
asymptomatic autoimmune thyroiditis was an impor-
tant risk factor for coronary heart disease. These
findings, however, were not confirmed by other
studies (7, 8, 11, 15).
In our population-based study, we examined
whether subclinical hypothyroidism and thyroid auto-
immunity are associated with aortic atherosclerosis
and myocardial infarction in elderly women. We
conducted our study in a random sample of 1149
postmenopausal women who were participating in
the Rotterdam Study.
Methods
The Rotterdam Study
The Rotterdam Study is a population-based co-
hort study designed to assess the occurrence and
clarify the determinants of chronic diseases in an
aging population (16). The cohort includes 3105
men and 4878 women at least 55 years of age (78%
of the eligible population) living in a defined district
in Rotterdam, the Netherlands. Baseline data were
collected from August 1990 to July 1993. During a
home interview, a trained research assistant gath-
ered information on current and past health, med-
ication, lifestyle, and risk factors for chronic dis-
eases. Participants were subsequently invited to visit
a research center for clinical examination. The study
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Erasmus University Medical School, Rotterdam, the
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Clinical Examination and Laboratory Methods
Height and weight were measured while each
participant was wearing indoor clothing without
shoes. Body mass index was computed as weight
divided by height squared. A trained research assis-
tant measured sitting systolic and diastolic blood
pressure with a random-zero sphygmomanometer
after 5 minutes of rest, and a standard 12-lead
electrocardiogram was obtained (ACTA electrocar-
diogram recorder, Esoate, Florence, Italy).
Venipuncture was performed, and nonfasting se-
rum samples were collected. The samples were im-
mediately put on ice and were processed within 30
minutes, after which they were kept frozen at
220 °C. We used an automated enzymatic proce-
dure to determine serum total cholesterol level (17).
High-density lipoprotein (HDL) cholesterol levels
were measured in a similar manner after precipita-
tion of the non-HDL cholesterol fraction. Total pro-
tein level was measured by using the biuret method,
albumin level was measured by using the bromocresol-
green method, and creatinine concentration was
measured by using an enzymatic colorimetric
method. (All products were manufactured by
Boehringer Mannheim, Mannheim, Germany, cur-
rently Roche Diagnostics, Basel, Switzerland.) We
assayed levels of TSH by using TSH Lumitest (Hen-
ning, Berlin, Germany, currently Brahms, Berlin,
Germany) (18). When TSH concentrations were ab-
normal (.4.0 mU/L or ,0.4 mU/L), serum free
thyroxine levels were measured with an in vitro
immunodiagnostic reagent (Ortho-Clinical Diagnos-
tics, Amersham, England, United Kingdom); values
between 11 and 25 pmol/L (0.9 and 1.9 ng/dL) were
considered normal. Serum antibodies to thyroid per-
oxidase were assessed by using enzyme-linked im-
munosorbent assay (Milenia, DPC, Los Angeles,
California); test results were considered positive if
levels were greater than 10 IU/mL.
Thyroid Definitions
Subclinical hypothyroidism was defined as a TSH
level greater than 4.0 mU/L in the presence of a
normal free thyroxine level (11 to 25 pmol/L [0.9 to
1.9 ng/dL]). Clinical hypothyroidism was defined as
a TSH level greater than 4.0 mU/L and a decreased
free thyroxine level (,11 pmol/L [,0.9 ng/dL]) (4).
Euthyroidism was defined as a normal TSH level
(0.4 to 4.0 mU/L).
Aortic Atherosclerosis
Aortic atherosclerosis was assessed on a lateral
radiographic film of the lumbar spine, which was
obtained from a fixed distance while the participants
were seated. A researcher who was unaware of the
participants’ thyroid status diagnosed atherosclerosis
off-line by detecting calcified deposits in the abdom-
inal aorta, as described elsewhere (19, 20). Calcifi-
cation was considered present when linear densities
were found in an area parallel and anterior to the
lumbar spine (L1 to L4). We classified aortic ath-
erosclerosis as mild, moderate, or severe, according
to the length of the involved area (#1 cm, 2 to 5
cm, and .5 cm, respectively). Because of a rela-
tively small number of participants in the categories
of aortic atherosclerosis, we combined severity
grades into two categories—“present” or “absent”—
for analysis.
The validity of radiographic assessment of aortic
atherosclerosis has been studied by comparing re-
sults of this method with data obtained at autopsy.
Radiographic assessment was shown to be highly
specific, and in most cases visible calcification rep-
resented advanced intima atherosclerosis (21). A
comparison study involving computed tomography
was performed at our department. In 56 unselected
elderly persons, aortic calcifications were indepen-
dently assessed by radiography and computed to-
mography. Calcifications were detected on abdomi-
nal radiography in 32 persons. In all but 1 person,
these calcifications were shown to be located in the
aorta on the corresponding computed tomography
images (20).
Aortic calcification is known to be associated
with risk factors for cardiovascular disease (19, 20)
and with atherosclerosis at other sites (22) and pre-
dicts cardiovascular morbidity and mortality (23,
24). When aortic calcification (as detected by radi-
ography) was compared with coronary artery cal-
cium (as detected by electron-beam computed to-
mography) in 457 participants in the Rotterdam
Study, aortic calcification was present in 3.9% of
participants in the lowest tertile of coronary artery
calcium, in 13.7% of those in the middle tertile of
coronary artery calcium, and in 31.5% of those in
the highest tertile of coronary artery calcium
(P , 0.001 for trend, adjusted for age and sex).
These results indicate that aortic calcification is
strongly related to coronary calcification.
Myocardial Infarction at Baseline
The presence of myocardial infarction was as-
sessed by self-report and by analysis of the standard
12-lead electrocardiograms, which were stored digi-
tally and were analyzed by using the Modular Elec-
trocardiogram Analysis System (MEANS) (25, 26).
For participants who reported myocardial infarction
but had no electrocardiographic evidence of it, we
collected additional information from their general
practitioners or cardiologists. Myocardial infarction
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was confirmed if the information in the medical
records met standard diagnostic criteria. An experi-
enced cardiologist reviewed the electrocardiograms
of participants who had not reported myocardial
infarction but had electrocardiographic evidence of
it. In these participants, absence of symptoms was
confirmed by medical records review. When the car-
diologist confirmed myocardial infarction (silent
myocardial infarction), it was considered present.
We combined both types of myocardial infarction
into one variable for analysis. No information on
the thyroid status of participants was available at
assessment for myocardial infarction.
Follow-up Procedures
We collected data on incident myocardial infarc-
tion from baseline (1990 to 1993) until 1 April 1996.
Fatal and nonfatal events were reported by general
practitioners in the research area (in which 85% of
the study cohort resides) who cooperate with the
Rotterdam Study and provide information through
a computerized system. Research physicians verified
all information by checking participants’ medical
records at the general practitioners’ offices. In ad-
dition, we obtained letters from medical specialists
and discharge reports for hospitalized patients. Two
research physicians coded events independently ac-
cording to the International Classification of Dis-
eases, 10th Revision (27). If the two physicians dis-
agreed, they reached consensus in a separate
session. Subsequently, a medical expert in the field
reviewed all events coded by the research physicians
and verified that all coding rules had been applied
correctly. When discrepancies were found between
the coding of the medical expert and that of the
research physicians, the expert’s judgment was con-
sidered final. Myocardial infarction was defined as a
nonfatal or fatal myocardial infarction (ICD-10
codes I21–I23). When we compared our results with
data registered by the nationwide morbidity registry
of hospitals, we found that 98% of all incident
myocardial infarctions that occurred in Rotterdam
Study participants before 1 April 1996 had been
detected by our follow-up data collection system.
Selection of the Sample for Analysis
The selection of the sample for analysis is shown
in the Figure. We determined thyroid status in a
random sample of 1149 women after excluding
those who took amiodarone, which may nonsystem-
atically alter TSH levels (28). To obtain a reference
category that included only euthyroid women (those
Figure. Selection of sample for analysis. 1 5 selection of women for analysis of aortic atherosclerosis at baseline; 2 5 selection of women for analysis
of history of myocardial infarction at baseline; 3 5 selection of women for analysis of incident myocardial infarction.
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whose TSH levels were within the normal range),
we excluded women with clinical hypothyroidism
(n 5 13); those with a decreased TSH level (,0.4 m
U/L), which indicated clinical hyperthyroidism (free
thyroxine level . 25 pmol/L [.1.9 ng/dL]) or sub-
clinical hyperthyroidism (free thyroxine level, 11 to
25 pmol/L [0.9 to 1.9 ng/dL]) (n 5 73); and/or those
taking thyroid medication (L-thyroxine or thyrostatic
medication [propylthiouracil, carbimazole, or thi-
amazole]) (n 5 10).
Of the 1055 women remaining, we excluded
those for whom data were missing (n 5 50) or im-
proper (n 5 30); therefore, 975 were included in
our analysis of aortic atherosclerosis (Figure, selec-
tion 1). Data on myocardial infarction at baseline
were available for 994 women (Figure, selection 2).
At the time of analysis, 19 women had not been
completely followed because of linking problems be-
tween their general practitioners’ medical records
and our computerized registration system. There-
fore, until 1 April 1996, completed follow-up for
analysis of incident myocardial infarction was avail-
able for 1036 women, covering an average period
(6SD) of 4.6 6 0.7 years (Figure, selection 3).
Statistical Analysis
We used linear regression analysis to compare
the age-adjusted continuous baseline characteristics
of euthyroid women and women with subclinical
hypothyroidism. The chi-square test was used to
compare proportions of women who smoked in both
groups and to compare proportions of women who
had subclinical hypothyroidism and antibodies to thy-
roid peroxidase according to vascular disease status.
Multivariate logistic regression analysis was used
to evaluate the association of aortic atherosclerosis
and myocardial infarction as assessed at baseline
(history of myocardial infarction) with subclinical
hypothyroidism. For women with subclinical hypo-
thyroidism, we computed the risk for incident myo-
cardial infarction (both fatal and nonfatal) during
follow-up by using Cox proportional hazards regres-
sion analysis. In this analysis, we excluded women
with a history of myocardial infarction (n 5 79). We
adjusted all analyses for age by entering age as a
continuous variable in the regression model; we
subsequently adjusted analyses for body mass index,
cholesterol and HDL cholesterol level, systolic and
diastolic blood pressure, and smoking status (never,
past, or current). To ensure that comparisons be-
tween models were valid, the age-adjusted models
included the number of participants for whom in-
formation was available on all of the covariates for
which the multivariate model was adjusted.
We performed additional analyses after excluding
women who took b-blockers (alprenolol, oxprenolol,
pindolol, propranolol, timolol, and sotalol) (n 5 37)
because these drugs may influence TSH levels (29).
In addition, we used logistic regression analysis to
compare the associations of aortic atherosclerosis
and history of myocardial infarction with subclinical
hypothyroidism in women who had subclinical hy-
pothyroidism and antibodies to thyroid peroxidase
relative to those in euthyroid women who did not
have antibodies to thyroid peroxidase. We also used
logistic regression analysis to compare the frequency
of aortic atherosclerosis and history of myocardial
infarction in women with antibodies to thyroid per-
oxidase and women without antibodies to thyroid
peroxidase, independent of thyroid status.
The attributable risk percentage, or etiologic
fraction, and the population attributable risk per-
centage for subclinical hypothyroidism associated
with incident myocardial infarction were calculated
(30). For purposes of comparison, we calculated the
attributable risk percentage and the population at-
tributable risk percentage for the four major, classic
risk factors for cardiovascular disease—hypercholes-
Table 1. Baseline Characteristics of the Study Sample
Variable Euthyroid Women
(n 5 931)*
Women with Subclinical Hypothyroidism
(n 5 124)†
Mean age 6 SD, y 68.9 6 7.4 69.0 6 7.9
Mean body mass index 6 SD, kg/m2 26.7 6 4.1 27.1 6 3.8
Mean systolic blood pressure 6 SD, mm Hg 138 6 21 137 6 22
Mean diastolic blood pressure 6 SD, mm Hg 73 6 11 73 6 11
Mean total cholesterol level 6 SD, mmol/L (mg/dL) 7.0 6 1.2 (271 6 46) 6.7 6 1.0 (259 6 39)‡
Mean high-density lipoprotein cholesterol level 6 SD, mmol/L (mg/dL) 1.5 6 0.4 (58 6 15) 1.4 6 0.4 (54 6 15)§
Mean total protein level 6 SD, g/L 71.0 6 4.9 71.7 6 4.7
Mean albumin level 6 SD, g/L 42.7 6 2.4 43.0 6 2.5
Mean creatinine concentration 6 SD, mmol/L (mg/dL) 77.6 6 13.9 (0.9 6 0.2) 77.4 6 14.7 (0.9 6 0.2)
Smoking status, % (n)
Never 50 (466) 51 (63)
Past 29 (272) 30 (37)
Current 19 (176) 19 (23)
* For some euthyroid women, data were missing on body mass index (n 5 7), blood pressure and HDL cholesterol level (n 5 4), albumin level (n 5 2), creatinine concentration
(n 5 1), and smoking habits (n 5 17).
† Data on body mass index, blood pressure, and smoking habits were each missing for 1 woman.
‡ P , 0.05, adjusted for age.
§ P 5 0.07, adjusted for age.
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terolemia (total cholesterol level $ 8.0 mmol/L
[$309 mg/dL]), hypertension (systolic blood pres-
sure $ 160 mm Hg and/or diastolic blood pres-
sure $ 95 mm Hg, and/or antihypertensive medica-
tion use), smoking status (current and past
compared with never), and diabetes mellitus (use of
antidiabetic medication or a random postload glucose
level .11.1 mmol/L [200 mg/dL])—associated with
incident myocardial infarction in all female partici-
pants of the Rotterdam Study (n 5 4878).
All measures of association are presented with
95% CIs. A P value less than 0.05 was considered
statistically significant. We used SPSS 8.0 for Win-
dows (SPSS, Inc., Chicago, Illinois) for all analyses.
Results
Before exclusion of clinically hypothyroid women,
women with a decreased TSH level, and women
using thyroid medication, the prevalence of subclin-
ical hypothyroidism in the study sample was 10.8%.
The baseline characteristics of the study sample are
shown in Table 1. Women with subclinical hypothy-
roidism did not differ from euthyroid women with
regard to age, body mass index, blood pressure,
total protein level, albumin level, creatinine concen-
tration, or smoking status but had significantly lower
levels of total cholesterol and borderline signifi-
cantly lower levels of HDL cholesterol in age-ad-
justed comparisons.
Table 2 shows the characteristics of participants
according to vascular disease status. Fifty-three per-
cent of participants (n 5 560) had aortic atheroscle-
rosis at baseline, and 7.5% (n 5 79) had a history of
myocardial infarction. Subclinical hypothyroidism
was present in 11.8% of women in our sample for
analysis. Women who had aortic atherosclerosis and
a history of myocardial infarction had a higher prev-
alence of subclinical hypothyroidism and subclinical
hypothyroidism accompanied by antibodies to thy-
roid peroxidase than those who did not have these
diseases. The prevalence of thyroid autoimmunity
independent of thyroid status itself did not differ
significantly among the specific subgroups. Among
women with subclinical hypothyroidism, concentra-
tions of TSH were higher in those with antibodies
to thyroid peroxidase than in those without such
antibodies (age-adjusted geometric means, 6.6
mU/L [CI, 6.1 to 7.1 mU/L] and 5.4 mU/L [CI, 5.0
to 5.8 mU/L], respectively; P 5 0.001). Independent
of thyroid status, TSH levels were also higher in
women who had antibodies to thyroid peroxidase
than in those who did not (geometric means, 2.4
mU/L [CI, 2.2 to 2.6 mU/L] and 1.6 mU/L [CI, 1.5
to 1.7 mU/L], respectively; P , 0.001).
Subclinical hypothyroidism was associated with a
greater prevalence of aortic atherosclerosis. The
odds ratio for aortic atherosclerosis (1.7 [CI, 1.1 to
2.6]) was increased in women with subclinical hypo-
thyroidism (Table 3). Women with subclinical hypo-
thyroidism also had a greater prevalence of myocar-
dial infarction than euthyroid women (odds ratio,
2.3 [CI, 1.3 to 4.0]) (Table 3). Additional adjust-
ment for body mass index, total cholesterol and
HDL cholesterol levels, systolic and diastolic blood
pressure, and smoking status did not affect these
associations, nor did exclusion of participants who
used b-blockers (data not shown). During an aver-
age follow-up of 4.6 years, 16 women had a first
incident myocardial infarction. When we used a Cox
proportional hazards regression analysis in women
with subclinical hypothyroidism, a statistically non-
significant adjusted relative risk of 2.5 (CI, 0.7 to
9.1) was observed for myocardial infarction.
Women with subclinical hypothyroidism and anti-
bodies to thyroid peroxidase had a greater prev-
alence of aortic atherosclerosis than euthyroid women
without antibodies to thyroid peroxidase (odds ratio,
1.9 [CI, 1.1 to 3.6]) (Table 3). The presence of
antibodies to thyroid peroxidase increased the odds
ratio for a history of myocardial infarction to 3.1
(CI, 1.5 to 6.3) in women who had subclinical hy-
pothyroidism compared with euthyroid women who
did not have antibodies to thyroid peroxidase (Table
3). Because only one woman with subclinical hypo-
thyroidism and antibodies to thyroid peroxidase had
myocardial infarction during follow-up, we were not
Table 2. Characteristics of Women according to Vascular Disease Status
Characteristic All Women
(n 5 1055)
Women with Aortic
Atherosclerosis
(n 5 560)
Women with a History of
Myocardial Infarction
(n 5 79)
Mean age 6 SD, y 68.9 6 7.5 70.7 6 7.4 71.1 6 6.9
Median thyroid-stimulating hormone level (25th, 75th percentile), mU/L 1.7 (1.1, 2.7) 1.7 (1.1, 2.8) 2.0 (1.2, 3.4)
Women with subclinical hypothyroidism, % (n) 11.8 (124) 13.9 (78)* 21.5 (17)†
Women with subclinical hypothyroidism and antibodies to thyroid
peroxidase, % (n) 5.8 (61) 7.1 (40)* 13.9 (11)†
Women with antibodies to thyroid peroxidase, % (n) 21.6 (228) 21.4 (120) 26.6 (21)
* P , 0.05 compared with women without the specific vascular disease status (chi-square test).
† P , 0.01 compared with women without the specific vascular disease status (chi-square test).
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able to compute the corresponding risk for incident
myocardial infarction. No association was found be-
tween the presence of antibodies to thyroid perox-
idase and history of myocardial infarction or be-
tween aortic atherosclerosis and history of myocardial
infarction when thyroid status was not altered (data
not shown).
From our data, we calculated an attributable risk
percentage of 60 and a population attributable risk
percentage of 14 for subclinical hypothyroidism as-
sociated with myocardial infarction (Table 4). If
subclinical hypothyroidism is assumed to be causally
related to myocardial infarction, our findings sug-
gest that it contributed to 60% of cases of myocar-
dial infarction among women affected by subclinical
hypothyroidism and that it was involved in the
pathogenesis of 14% of all myocardial infarctions in
the study sample. For purposes of comparison, the
attributable risk percentages and the population
attributable risk percentages for hypercholesterol-
emia, hypertension, smoking, and diabetes associ-
ated with myocardial infarction in all female partic-
ipants in the Rotterdam Study are presented in
Table 4.
Discussion
Our results show that subclinical hypothyroidism
is highly prevalent among elderly women and is
associated with a greater frequency of aortic athero-
sclerosis and myocardial infarction. Among women
with subclinical hypothyroidism, these associations
are slightly stronger in those who have antibodies to
thyroid peroxidase. Thyroid autoimmunity itself is
not associated with aortic atherosclerosis or myocar-
dial infarction.
One limitation of our study is the cross-sectional
nature of the design, which necessitates careful in-
terpretation of the results. The relative risk for
myocardial infarction in women with subclinical hy-
pothyroidism in the prospective part of our study
was similar to the point estimate in the cross-sec-
tional part of our study. However, the CI was wide
and included 1.0. Furthermore, we must consider
the fact that elevated TSH levels may be caused by
nonthyroidal illness (31, 32). However, we excluded
women with a low free thyroxine level and observed
that women with subclinical hypothyroidism did not
differ from euthyroid women in levels of total pro-
tein, albumin, and creatinine. Therefore, it is highly
unlikely that nonthyroidal illness affected the valid-
ity of our results. Serum samples were obtained only
from women who visited the research center. We
assume that the nonresponse for the visit to the
research center will not depend on subclinical hy-
pothyroidism differently among persons with or
without the presence of cardiovascular disease,
making selection bias unlikely. Furthermore,
follow-up information was not available for all study
participants as a result of logistic reasons. Because
we have no reason to assume that the relation be-
tween subclinical hypothyroidism and myocardial in-
farction in women with complete follow-up data
differs from this association in those without follow-
up data, we do not believe that this lack of infor-
mation influenced the validity of our results.
Approximately 11% of women in our sample had
a TSH level greater than 4 mU/L. This prevalence
closely resembles that reported in women in the
Wickham survey (5), the Framingham Study (6),
and a study in community-dwelling elderly persons
(33). Among all women in our sample for analysis,
13 (1.1%) had unrecognized overt thyroid failure
characterized by an elevated TSH level (.4.0
mU/L) and an abnormal free thyroxine level (,11
pmol/L [0.9 ng/dL]), which is in agreement with
reports of prevalence found during screening (4).
Table 3. Odds Ratios for Aortic Atherosclerosis and Myocardial Infarction*
Variable Condition
Present
Condition
Absent
Odds Ratio
(95% CI)†
Odds Ratio
(95% CI)‡
n
Aortic atherosclerosis
Women with subclinical hypothyroidism 77 37 1.7 (1.1–2.6) 1.9 (1.2–3.1)
Euthyroid women 474 376 1§ 1§
Women with subclinical hypothyroidism and antibodies to thyroid peroxidase 39 16 1.9 (1.1–3.6) 2.2 (1.1–4.3)
Euthyroid women without antibodies to thyroid peroxidase 398 301 1§ 1§
Myocardial infarction
Women with subclinical hypothyroidism 17 99 2.3 (1.3–4.0) 2.3 (1.3–4.2)
Euthyroid women 61 806 1§ 1§
Women with subclinical hypothyroidism and antibodies to thyroid peroxidase 11 46 3.1 (1.5–6.3) 3.5 (1.7–7.4)
Euthyroid women without antibodies to thyroid peroxidase 52 660 1§ 1§
* The number of women may not be exactly the same as in Table 2 because data on some covariates were missing.
† Adjusted for present age.
‡ Adjusted for present age, body mass index, cholesterol level, high-density lipoprotein cholesterol level, systolic and diastolic blood pressure, and smoking status (current, past, or never).
§ Reference risk.
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These data suggest that our sample is representative
of the general population.
Several studies on the association between coro-
nary heart disease and subclinical hypothyroidism
have been done. Our results agree with those of
previous case–control studies that also showed an
association between subclinical hypothyroidism and
coronary heart disease in elderly women (9, 10).
However, a Finnish study that presented results of
men and women together provided no evidence that
latent thyroid failure is associated with coronary
heart disease (7). Female patients with coronary
heart disease were shown to have significantly lower
serum levels of TSH than controls; however, sub-
clinical hypothyroidism did not seem to be related
to the presence of coronary heart disease (11). In
the Wickham survey, no cross-sectional association
with ischemic heart disease was observed, but a
weak association between minor electrocardio-
graphic changes and minor degrees of hypothyroid-
ism was found in women (8).
Data on atherosclerosis and subclinical hypothy-
roidism are scarce. A case–control study in elderly
women suggested an association between subclinical
hypothyroidism and peripheral arterial disease (34).
We are the first to describe an association between
subclinical hypothyroidism and atherosclerosis as
assessed by a noninvasive measurement in a general
population sample. Aortic atherosclerosis was diag-
nosed by radiographic detection of calcified deposits
in the abdominal aorta, which has been shown to be
a highly specific technique for the measurement of
aortic intima atherosclerosis (21). False-negative
misclassification may have occurred in our study,
but it was probably independent of thyroid status
and therefore may have affected our results only by
causing us to underestimate the association. Be-
cause we found that subclinical hypothyroidism was
associated with both atherosclerosis and myocardial
infarction, our data may indicate that atherosclero-
sis is involved in the mechanism by which subclinical
hypothyroidism and myocardial infarction are asso-
ciated.
Several mechanisms that may be involved with
the association of subclinical hypothyroidism with
atherosclerosis and myocardial infarction can be
considered. A common cause of thyroid failure in
elderly women is autoimmune thyroiditis (6, 35). It
has been suggested that pathologic immune reactiv-
ity (for example, immune complex–mediated vascu-
lar damage) may be important in the association of
autoimmune thyroiditis with coronary heart disease
(36). However, the literature on this association is
controversial. Some studies have described an asso-
ciation between thyroid autoimmunity and coronary
heart disease (9, 10, 12, 14, 37), and other studies
have not (7, 8, 11, 15). Different uses of various
generations of antibody assays and different defini-
tions of thyroid autoimmunity may have played a
role in these discrepant findings. We found no as-
sociation between the presence of antibodies to thy-
roid peroxidase itself and aortic atherosclerosis or
myocardial infarction, which weakens the notion
that a pathologic immune reactivity is important.
We found that associations between subclinical hy-
pothyroidism and aortic atherosclerosis or myocar-
dial infarction were slightly stronger when subclini-
cal hypothyroidism was accompanied by antibodies
to thyroid peroxidase. This suggests that subclinical
hypothyroidism, which is thought to be more severe
and lasting in the presence of thyroid antibodies,
contributes to the pathogenesis of cardiovascular
disease.
Some authors found a disturbance in the athero-
genic lipid metabolism in patients with subclinical
hypothyroidism (38–42), whereas other studies did
not (43–45). Although in our study the total cho-
lesterol level was higher in women with overt hypo-
thyroidism than in euthyroid women (data not
shown), we did not find that total cholesterol level
was higher in women with subclinical hypothyroid-
ism than in euthyroid women. High-density lipopro-
tein and total cholesterol levels provided no patho-
physiologic explanation for the association of
subclinical hypothyroidism with aortic atherosclero-
sis and myocardial infarction. Other lipids—such
as low-density lipoprotein cholesterol level, en-
hanced low-density lipoprotein oxidation (46), tri-
glyceride level, and lipoprotein(a) level (42)—may
be responsible for the association between subclin-
ical hypothyroidism and cardiovascular disease, but
we did not measure these factors.
Other mechanisms that may be involved in the
association between subclinical hypothyroidism and
cardiovascular disease can be derived from experi-
mental data. In vitro, thyroid hormones inhibit
Table 4. Attributable Risk Percentages and Population
Attributable Risk Percentages for Subclinical
Hypothyroidism and Classic Risk Factors for
Cardiovascular Disease Associated with Incident
Myocardial Infarction in Women in the
Rotterdam Study
Risk Factor Age-Adjusted
Relative Risk*
Attributable
Risk
Population
Attributable Risk
%
Subclinical hypothyroidism 2.5 60 14
Hypercholesterolemia 2.4 58 18
Hypertension 1.6 38 14
Smoking 2.0/1.2† 50/17‡ 15
Diabetes mellitus 2.4 58 14
* Determined by using Cox proportional hazards regression analysis.
† Age-adjusted relative risk and attributable risk percentage for current compared with
never smokers.
‡ Age-adjusted relative risk and attributable risk percentage for past compared with
never smokers.
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collagen-induced platelet aggregation (47, 48) and
directly relax smooth muscle (49). These effects may
be important if thyroid hormones have the same
effects in adult humans, although in subclinical hypo-
thyroidism, by definition, levels of thyroid hormones
are not decreased. Hypothyroidism is accompanied
by a hypercoagulable state (50), increased blood
viscosity (51), and a greater plasma concentration of
total homocysteine (52); if these factors are also
seen in subclinical hypothyroidism, they may account
for atherosclerotic and ischemic disorders.
In conclusion, we found that subclinical hypothy-
roidism is highly prevalent in elderly women and is
strongly and independently associated with aortic
atherosclerosis and myocardial infarction. The pop-
ulation attributable risk percentage for subclinical
hypothyroidism associated with myocardial infarc-
tion was within the range of that for known major
risk factors for cardiovascular disease. Additional
research should be done to determine whether this
association can be confirmed in a prospective study.
If not, subsequent studies may focus on the effec-
tiveness of possible therapies for subclinical hypo-
thyroidism in elderly women and the desirability of
screening such women for this disorder.
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